Teplizumab can delay the onset of the chronic disease by reprogramming the immune system to stop it mistakenly attacking pancreatic cells which produce insulin. Sam, 14, from Kings Norton ...

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease ...

The biotech picked up rights to teplizumab from MacroGenics in 2010, eight years after Lilly abandoned its development following a failed phase 3 trial in newly-diagnosed type 1 diabetes patients.

Immunotherapy. 2011;3(11):1303-1306. Costimulation blockade has been proposed as a potential treatment in autoimmune disorders. As the induction of Tregs is not dependent on the CD28-B7 pathway ...